Zobrazeno 1 - 10
of 15
pro vyhledávání: ''
Autor:
Piotr Rutkowski, Paweł Rogala, Magdalena Wiśniewska, Anna M. Czarnecka, Adrianna Gęga-Czarnota, Bożena Cybulska-Stopa, Łukasz Galus, Tomasz Kubiatowski, Paweł Teterycz, Marcin Rajczykowski, Jacek Mackiewicz, Marek Ziobro, Robert Dziura, Rafał Suwiński
Publikováno v:
Melanoma Research. 30:465-471
Despite considerable progress made in the treatment of patients with advanced melanoma, the majority of the patients treated with BRAF and mitogen-activated protein inhibitors (BRAFi and MEKi) experience a disease progression due to acquired resistan
Publikováno v:
Melanoma Research. 29:501-509
In several cancers, tumor progression is associated with the infiltration of tumor-associated macrophages (TAMs). The aim was to evaluate the prognostic significance of expression of CD163 and CD68 (TAMs' markers) and their correlation with vascular
Autor:
Zeinab Jradi, Benjamin Weide, Annette Pflugfelder, Thomas Eigentler, Friedegund Meier, Laura Held, Sail Nawaf Rashid Abusaif, Claus Garbe
Publikováno v:
Melanoma Research. 23:396-401
Vemurafenib is a highly efficient BRAF inhibitor for metastatic melanoma patients carrying the V600 mutation: progression-free survival is prolonged to ∼ 6 months and 50-80% of the patients show objective tumor responses. S100B and lactate dehydrog
Autor:
Massimiliano Petrini, Claudia Brolli, Anna Maria Granato, Linda Valmorri, Laura Fiammenghi, Angela Riccobon, Elena Pancisi, Emanuela Scarpi, Ruggero Ridolfi, Massimo Guidoboni, Laura Ridolfi, Stefania Vittoria Luisa Nicoletti, Mirna Selva, Valentina Ancarani
Publikováno v:
Melanoma Research. 21:524-529
Dendritic cells (DCs) are unique specialized antigen-presenting cells capable of priming naive T cells and inducing antigen-specific cytotoxic T lymphocytes. This study presents an update of clinical results from a DC-based phase I-II clinical vaccin
Autor:
Ben Y. Zhang, William F. Elmquist, Arkadiusz Z. Dudek, Chul Kim, Vanna Chiarion-Sileni, Tulasi Gummadi, Lisa A. Kottschade, Jacopo Pigozzo, Rajendar K. Mittapalli, Sara Valpione
Publikováno v:
Melanoma research. 25(1)
The impact of BRAF mutations in metastatic melanoma on the incidence of brain metastases and melanoma prognosis and the effect of BRAF inhibitors on the incidence of brain metastases has not been defined. Therefore, a retrospective analysis of patien
Autor:
Henk H. Hartgrink, Cornelis J.H. van de Velde, Saidja L Noter, Rob A. E. M. Tollenaar, Jan E.E. Keunen, Peter J. K. Kuppen, Milan E. J. Pijl, Joost Rothbarth, Fred G.J. Tijl
Publikováno v:
Melanoma Research. :67-72
Uveal melanoma is the most common primary intraocular tumour in adults. After treatment of the primary tumour, up to 50% of patients will ultimately develop metastases. Treatment options for metastases are limited. When uveal melanoma metastases are
Autor:
Theresa Smith, Omar Eton, Julie A. Ellerhorst, Agop Y. Bedikian, Nicholas Papadopoulos, Carl Plager
Publikováno v:
Melanoma Research. :63-66
In four clinical trials in mostly chemotherapy-naive patients with metastatic melanoma, paclitaxel was found to be effective with a response rate of 16%. In vitro studies have shown that following exposure of cancer cells to paclitaxel for 1 h, sensi
Autor:
Edward Arrowsmith, John D. Hainsworth, Jeffrey R. Infante, Kent C. Shih, Ralph J. Hauke, Mark S. Rubin
Publikováno v:
Melanoma research. 23(6)
This phase II trial examined the efficacy and toxicity of first-line treatment with everolimus, paclitaxel, and carboplatin in patients with advanced melanoma. Seventy patients with metastatic or locally advanced unresectable melanoma who had been un
Autor:
Paolo Fava, Simona Osella-Abate, Tiziana Nardò, Alessandra Comessatti, Maria Grazia Bernengo, Paola Savoia, Pietro Quaglino
Publikováno v:
Melanoma research. 20(3)
Unknown melanoma occurs as metastasis to skin, nodes or viscera, without a detectable cutaneous primary tumour. We reviewed our database of 4881 melanoma patients, diagnosed and followed up prospectively for a 33-year period. We identified 93 cases o
Autor:
Gerald Langmann, Navid Ardjomand, Ingrid Boldin, Gerold Schwantzer, Beate J. Wegscheider, Yosuf El-Shabrawi, Eva Richtig
Publikováno v:
Melanoma research. 15(6)
Tyrosinase-based reverse transcriptase-polymerase chain reaction (RT-PCR) is a method for the detection of circulating melanoma cells in peripheral blood. To our knowledge, no long-term studies on the prognostic impact of tyrosinase PCR in uveal mela